Search
for
Sort by
Research 571–600 of 582
- Yangyin Qingre Huoxue Method in Traditional Chinese Medicine Ameliorates Atherosclerosis in ApoE<sup>−/−</sup> Mice Suffering from High-Fat Diet and HSP65 Aggression
- Inflammatory auxo-action in the stem cell division theory of cancer
- Intradermal Local Injection of Autologous Cell‐Free Fat Extract for the Treatment of Refractory Postinflammatory Hyperpigmentation
- Alleviation of Severe Skin Insults Following High-Dose Irradiation with Isolated Human Fetal Placental Stromal Cells
- Hypoxia-Mesenchymal Stem Cell Exosomes As A Novel Therapy Targeting Socs3/Stat3 Signaling In Androgenic Alopecia
- Molecular and cellular mechanisms of natural cosmetics and medical treatment in skin-antiaging: A review article
- Therapeutic Potential of Extracellular Vesicles (Exosomes) Derived From Platelet‐Rich Plasma: A Literature Review
- Thrombophilia and Polycythemia in a Woman With Budd-Chiari Syndrome
- Table_1_Bioinformatics and Network Pharmacology Identify the Therapeutic Role and Potential Mechanism of Melatonin in AD and Rosacea.xlsx
- A cross-sectional study of clinical, dermoscopic, histopathological, and molecular patterns of scalp melanoma in patients with or without androgenetic alopecia
- Ovarian Hyperthecosis Presenting as Polycythemia
- TRANSMEDCON 2022: E-Poster Abstracts
- Under Development JAK Inhibitors for Dermatologic Diseases
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Jak inhibitors in the treatment of alopecia areata - a literature review
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- IN-SILICO STUDY OF BIOACTIVE COMPOUNDS OF NATURAL MATERIALS AS A JAK- SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION INHIBITOR FOR ANTI-ALOPECIA
- Janus Kinase inhibitors in dermatology: a review
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature